Moleculin Biotech, Inc. (MBRX)

According to InvestingPro analysis, ... The platform’s Fair Value analysis suggests the stock may be undervalued at current levels. For deeper insights, investors can access a comprehensive Pro Research Report covering MBRX and 1,400+ other US equities....

Walter Klemp discussed preliminary results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for relapsed or refractory AML.

Is it a better buy than SpaceX and all of the Magnificent Seven stocks? When viewed in the context of how much it could grow your money over time, I think it is. And since the company plans to report second-quarter earnings Aug.

Initiate MBX Biosciences (MBXX) as a speculative buy: de-risked Canvuparatide, differentiated long-acting dosing, strong Phase 2 data & cash runway—read...

Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did not reach statistical significance.